Back to News
Market Impact: 0.15
Glaukos' Epioxa Shows Durable Three-Year Results In Keratoconus
Source: Nasdaq
Healthcare & Biotech
Glaukos reported three-year results from a Phase 3 extension study of Epioxa, its epithelium-on corneal cross-linking therapy for keratoconus. The report provided no details on the study outcomes.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
GKOS0.20
More News
- Glaukos: The Second J-Code Rewrites The Risk Math
- Teva wins FDA approval for monthly schizophrenia injection Weltruza
- BofA downgrades Alignment Healthcare stock rating on star rating drop
- Humana Stock Jumps on Raised Medicare Advantage Ratings
- Premarket movers: Humana rallies; SpaceX deal sends telco stocks down
- Baird upgrades Humana stock rating on margin recovery outlook